Comparison Between Biopsied and Non-biopsied Intracytoplasmatic Sperm Injection (ICSI) Embryos and Natural Pregnancy Embryos
Comparison Between Biopsied and Non-biopsied Intracytoplasmatic Sperm Injection (ICSI) Embryos and Natural Pregnancy Embryos
As Pre Implantation Genetic Screening (PGS) becomes now a replacement modality and trend
 gaining popularity among physicians and patients on claiming its ability to settle on the
 simplest genetically normal embryo,so it had been logical to review if taking cells from the
 embryo in its early development will or won't affect its growth as compared to the previous
 standard technique of ICSI and in comparison to a normally conceived embryos the study also
 will question if the parameters of the prenatal biochemical standard parameters will have any
 differences if the embryo is already genetically tested embryo and compare these parameters
 with non PGS embryos and normally conceived embryos.
The women will be included in the study after pregnancy confirmation by ultrasound at week 6
 of gestation either by normal pregnancy or ICSI. For women in their 1st trimester of
 pregnancy, early ultrasound assessment will be done. Measurement of mean sac diameter (MSD)
 from 6 to 8 weeks ,crown-rump length (CRL) from 10 to 12 weeks. Combined tests will be done
 between 11weeks - 13 weeks+6 days (PAPP-A and free beta HCG). For women in their 2nd
 trimester of pregnancy, tests done will include the triple test (α-fetoprotein, free β HCG,
 and E3) will be done at 14 to 20 week . fetal ponderal index which is the inverse ratio of
 estimated foetal weight in grams to the third power of the femur length at weeks (20 to 24)..
 For women in their 3rd trimester of pregnancy, routine ultrasound assessment of fetal growth
 will be done including measurement of fetal ponderal index.at 32,34 and 36 weeks of
 gestation.
Inclusion Criteria:

 1. singleton pregnant women.

 2. between the age of 20 and 40 years.

 3. non-smokers.

 4. BMI must be between 19 and 40.

 Exclusion Criteria:

 1. Those with anti-phospholipid syndrome confirmed by serological tests

 2. Those with any hematological and immunological disorders

 3. women with uterine abnormalities that have not been corrected

 4. women with systemic diseases that cannot be controlled or managed